Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

We previously reported that bortezomib indirectly modulates transcription of DNA methyltransferase 1 (DNMT). We designed a phase I study of azacitidine (a direct DNMT inhibitor) plus bortezomib in acute myeloid leukemia (AML) to determine safety and tolerability. Twenty-three adults with relapsed/re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Walker, Alison R., Klisovic, Rebecca B., Garzon, Ramiro, Schaaf, Larry J., Humphries, Kristina, Devine, Steven M., Byrd, John C., Grever, Michael R., Marcucci, Guido, Blum, William
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3925754/
https://ncbi.nlm.nih.gov/pubmed/23952243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.833333
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares